MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

KalVista Pharmaceuticals Inc

Avatud

SektorTervishoid

12.86 2.47

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

12.47

Max

13.1

Põhinäitajad

By Trading Economics

Sissetulek

-6.2M

-49M

Aktsiakasum

-0.92

Kasumimarginaal

-3,702.322

Töötajad

150

EBITDA

4.4M

-41M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+112.58% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

10. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

4.6M

597M

Eelmine avamishind

10.39

Eelmine sulgemishind

12.86

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

KalVista Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. nov 2024, 21:11 UTC

Suurimad hinnamuutused turgudel

KalVista Pharmaceuticals Shares Rise 11% on Royalty Financing Deal, Stock Offering

Võrdlus sarnastega

Hinnamuutus

KalVista Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

112.58% tõus

12 kuu keskmine prognoos

Keskmine 27.38 USD  112.58%

Kõrge 39 USD

Madal 19 USD

Põhineb 10 Wall Streeti analüütiku instrumendi KalVista Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

10 ratings

10

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

11.76 / N/AToetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Very Strong Bullish Evidence

Pikk perspektiiv

Strong Bullish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.